Tilray Brands, Inc. (TLRY)

Tilray Brands' stock price has experienced several notable events and trends in the past six months. The company's market capitalization decreased by 18.77% over the past 30 days and by 19.69% over the past 12 months as of January 30, 2026. In August 2025, Tilray requested an extension to regain compliance with Nasdaq's listing standards. In October 2025, Tilray Brands held its First Quarter 2026 Earnings Call. In December 2025, Tilray Brands shares underwent a 1-10 reverse stock split. In January 2026, the company released its quarterly earnings results, reporting ($0.41) EPS, missing estimates, but revenue exceeded estimates. Analyst ratings have varied, with a consensus rating of "Reduce" and an average price target of $13.33. As of February 6, 2026, TLRY's price at $7.46 remained below key moving averages, indicating a bearish structure.

Demand for Tilray Brands' products and services, particularly in the cannabis sector, can exhibit seasonality. The company has strategically launched new cannabis product offerings for the summer season, indicating an awareness of increased consumer activity during this period. The agricultural nature of cannabis cultivation suggests that farming is an extremely seasonal business, where calibrating production with demand can lead to unpredictable results across quarters.

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company operating in the Medical sector, specifically in the Medical Products industry. Its business model is based on four segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of cannabis products. The Distribution segment involves the resale of pharmaceutical and wellness products. The Beverage segment produces and sells craft beer and premium spirits. The Wellness segment focuses on hemp-based food and wellness products. Tilray is a cannabis market leader in Canada and a significant supplier in Europe and has expanded into the U.S. craft beer market.

Tilray Brands has a broad international presence, with operations spanning Canada, the United States, Europe, Australia, and Latin America. Its medical cannabis products are supplied to 20 countries across five continents. Its European pharmaceutical distribution arm, CC Pharma, operates in Germany.

In the past year, Tilray Brands has engaged in activities that contribute to its brand reputation and market presence. CC Pharma was recognized as a TOP 100 Innovator in Germany. Breckenridge Distillery expanded its distribution through a new partnership in Illinois. Tilray Brands announced its 2025 summer cannabis collection. Tilray Brands launched a "Summer Shareability Campaign" under its Good Supply Cannabis brand.

The ownership structure of Tilray Brands stock includes institutional, retail, and individual investors. Approximately 11.70% of the company's stock is owned by Institutional Investors, 7.25% by Insiders, and 81.05% by Public Companies and Individual Investors. Major institutional shareholders include Amplify Alternative Harvest ETF, Simplex Trading, Llc, Group One Trading, L.p., PRFZ - Invesco FTSE RAFI US 1500 Small-Mid ETF, CNBS - Amplify Seymour Cannabis ETF, UBS Group AG, VT - Vanguard Total World Stock Index Fund ETF Shares, and YOLO - AdvisorShares Pure Cannabis ETF. Individual insiders who own company stock include Irwin D Simon, Carl A Merton, Denise M Faltischek, and Mitchell Gendel.